Survey: Oncologists Expect To Prescribe Onureg in AML

November 1

With the FDA’s approval last month of Onureg (azacitidine), people with acute myeloid leukemia (AML) now have an oral version of a longtime injectable treatment within that class. Zitter Insights found that more than half of oncologists polled are likely to prescribe the drug as a maintenance treatment for the condition.

On Sept. 1, the FDA approved Bristol-Myers Squibb Co. unit Celgene Corp.’s Onureg, a tablet, for the continued treatment of adults with AML who achieved first complete remission or CR with incomplete blood count recovery following intensive induction chemotherapy and who are not able to complete intensive curative therapy (RSP 9/20, p. 8).

0 Comments

Radar on Specialty Pharmacy

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. She also has written for Spotlight on Market Access since its 2017 launch. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at Hem Aware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

HOSP Forms to Advocate for Integrated Specialty Pharmacies November 1, 2020